Standout Papers

Cetuximab Monotherapy and... 2004 2026 2011 2018 2004 2012 2007 2010 2007 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
    2004 3.9k citations David Cunningham, Yves Humblet et al. New England Journal of Medicine profile →
  2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    2012 2.0k citations Axel Grothey, Eric Van Cutsem et al. The Lancet profile →
  3. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  4. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    2010 1.3k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
  5. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    2007 659 citations Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology profile →
  6. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
    2004 614 citations Eric Van Cutsem, Helgi van de Velde et al. Journal of Clinical Oncology profile →
  7. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    2009 501 citations Eric Van Cutsem, Walter L. Vervenne et al. Journal of Clinical Oncology profile →

Immediate Impact

9 by Nobel laureates 7 from Science/Nature 168 hit
Sub-graph 1 of 17

Citing Papers

Colorectal cancer
2024 Hit
Diagnosis and Treatment of Metastatic Colorectal Cancer
2021 Hit
72 intermediate papers

Works of Yves Humblet being referenced

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Hit
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
2010 Hit
and 19 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yves Humblet 12.9k 5.6k 2.8k 2.8k 2.8k 174 15.9k
Sabine Tejpar 11.2k 0.9× 4.3k 0.8× 5.3k 1.9× 3.7k 1.3× 2.1k 0.8× 214 15.4k
Fernando Rivera 10.2k 0.8× 4.7k 0.8× 1.9k 0.7× 1.9k 0.7× 2.6k 0.9× 168 12.9k
Christophe Louvet 14.8k 1.1× 6.1k 1.1× 2.4k 0.9× 1.9k 0.7× 3.6k 1.3× 278 17.7k
Joon Oh Park 9.1k 0.7× 7.6k 1.3× 2.1k 0.7× 4.5k 1.6× 1.6k 0.6× 387 16.1k
Fairooz F. Kabbinavar 12.9k 1.0× 8.8k 1.6× 1.8k 0.6× 7.8k 2.8× 3.4k 1.2× 175 21.8k
Marc Ychou 16.1k 1.2× 7.7k 1.4× 2.8k 1.0× 4.2k 1.5× 2.9k 1.0× 320 22.0k
Fotios Loupakis 8.3k 0.6× 3.6k 0.6× 2.8k 1.0× 3.1k 1.1× 2.2k 0.8× 315 11.6k
Philip B. Paty 13.2k 1.0× 3.7k 0.7× 2.2k 0.8× 2.5k 0.9× 2.1k 0.7× 301 18.0k
Jean‐Baptiste Bachet 11.3k 0.9× 4.2k 0.7× 1.8k 0.7× 2.5k 0.9× 893 0.3× 210 13.4k
Gabriella Fontanini 7.2k 0.6× 4.6k 0.8× 1.6k 0.6× 5.3k 1.9× 1.1k 0.4× 320 13.4k

All Works

Loading papers...

Rankless by CCL
2026